Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 3
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Fehr, Rainer Mekel, Odile C.L. Fintan Hurley, J. and Mackenbach, Johan P. 2016. Health impact assessment – A survey on quantifying tools. Environmental Impact Assessment Review, Vol. 57, p. 178.

    Hennessy, Deirdre A. Flanagan, William M. Tanuseputro, Peter Bennett, Carol Tuna, Meltem Kopec, Jacek Wolfson, Michael C. and Manuel, Douglas G. 2015. The Population Health Model (POHEM): an overview of rationale, methods and applications. Population Health Metrics, Vol. 13, Issue. 1,

    Miller, Anthony B. Gribble, Steve Nadeau, Claude Asakawa, Keiko Flanagan, William M. Wolfson, Michael Coldman, Andrew Evans, William K. Fitzgerald, Natalie Lockwood, Gina and Popadiuk, Cathy 2015. Evaluation of the natural history of cancer of the cervix, implications for prevention. The Cancer Risk Management Model (CRMM) – Human papillomavirus and cervical components. Journal of Cancer Policy, Vol. 4, p. 1.

  • International Journal of Technology Assessment in Health Care, Volume 29, Issue 2
  • April 2013, pp. 131-139


  • William K. Evans (a1), Michael C. Wolfson (a2), William M. Flanagan (a3), Janey Shin (a4), John Goffin (a5), Anthony B. Miller (a6), Keiko Asakawa (a7), Craig Earle (a8), Nicole Mittmann (a9), Lee Fairclough (a4), Jillian Oderkirk (a3), Philippe Finès (a3), Stephen Gribble (a3), Jeffrey Hoch (a10), Chantal Hicks (a3), D. Walter R. Omariba (a3) and Edward Ng (a3)
  • DOI:
  • Published online: 20 March 2013

Objectives: The aim of this study was to develop a decision support tool to assess the potential benefits and costs of new healthcare interventions.

Methods: The Canadian Partnership Against Cancer (CPAC) commissioned the development of a Cancer Risk Management Model (CRMM)—a computer microsimulation model that simulates individual lives one at a time, from birth to death, taking account of Canadian demographic and labor force characteristics, risk factor exposures, and health histories. Information from all the simulated lives is combined to produce aggregate measures of health outcomes for the population or for particular subpopulations.

Results: The CRMM can project the population health and economic impacts of cancer control programs in Canada and the impacts of major risk factors, cancer prevention, and screening programs and new cancer treatments on population health and costs to the healthcare system. It estimates both the direct costs of medical care, as well as lost earnings and impacts on tax revenues. The lung and colorectal modules are available through the CPAC Web site ( to registered users where structured scenarios can be explored for their projected impacts. Advanced users will be able to specify new scenarios or change existing modules by varying input parameters or by accessing open source code. Model development is now being extended to cervical and breast cancers.

Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

5.H Moller , L Fairley , V Coupland , et al.The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer. 2007;96:14841488.

7.National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395409.

8.T Winton , R Livingston , D Johnson , et al.Vinorelbine plus cisplatin versus observation in resected non-small cell lung cancer. N Engl J Med. 2005;352:25892597.

12.NH Segal , LB. Saltz Evolving treatment of advanced colon cancer. Annu Rev Med. 2009;60:207219.

15.BP Will , J-M Berthelot , C LePetit , et al.Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer. 2000;36:724735.

16.BP Will , C Le Petit , J-M Berthelot , et al.Diagnostic and therapeutic approaches for non-metastatic breast cancer in Canada, and their associated costs. Br J Cancer. 1999;79:14281436.

17.J-M Berthelot , BP Will , WK Evans , et al.Decision framework for chemotherapeutic interventions for metastatic non-small cell lung cancer. J Natl Cancer Inst. 2000;92:13211329.

18.WK Evans , BP Will , J-M Berthelot , et al.Breast cancer: Better care for less cost: Is it possible? Int J Technol Assess Health Care. 2000;16:11681178.

20.BP Will , J-M Berthelot , KM Nobrega , W Flanagan , WK. Evans Canada's Population Health Model (POHEM): A tool for performing economic evaluations of cancer control interventions. Eur J Cancer. 2001;37:17971804.

21.BP Will , KM Nobrega , J-M Berthelot , et al.First do no harm: Extending the debate on the provision of preventive tamoxifen. Br J Cancer. 2001;85:12801288.

23.SJ Winawer , AG Zauber , MN Ho , et al.Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med. 1993;329:19771981.

24.O Kronborg , C Fenger , J Olsen , OD Jorgensen , O. Sondergaard Randomized study of screening for colorectal cancer with fecal occult blood test. Lancet. 1996;348:14671471.

25.TR Church , JS Mandel , JH Bond , F. Ederer Colorectal cancer incidence reduction due to polyp removal: Results from the Minnesota trial. Gastroenterology. 2003;124 (Suppl 1):A55.

26.DA. Lieberman Screening for colorectal cancer. N Engl J Med. 2009;361:11791187.

27.J Horsman , W Furlong , D Feeney , G. Torrance The Health Utilities Index (HUI): Concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54.

32.WM Flanagan , CN McIntosh , J-M Berthelot , C. LePetit Deriving utility scores for co-morbid conditions: a test of the multiplicative model for combining individual condition scores. Popul Health Metr. 2006;4:13 doi:10.1186/1478–7954-4-13.

35.S Navaratnam , EV Kliever , J Butler , et al.Population-based patterns and cost management of metastatic non-small cell lung cancer after completion of chemotherapy until death. Lung Cancer. 2010;70:110115. doi:10.1016/j.lungcan.2010.01.012.

39.CA Butts , K Ding , L Seymour , et al.Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: Updated survival analysis of JBR-10. J Clin Oncol. 2009;28:2934.

40.WK Evans , R Feld , N Murray , et al.Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. Ann Int Med. 1987;107:451458.

43.DH Johnson , LH Einhorn , A Bartolucci , et al.Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Int Med. 1990;113:3338.

45.CA Perez , K Stanley , P Rubin , et al.A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung: Preliminary Report by the Radiation Therapy Oncology Group. Cancer. 1980;45:27442753.

47.R McGregor , P Vasudev , E Letourneau , et al.Background concentration of radon and radon daughters in Canadian homes. Health Phys. 1980;39:285289.

48.C Eheman , SJ Henley , R Ballard-Barbash , et al.Annual report to the nation on the status of cancer 1975–2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118:23382366. doi:10.1002/cncr.27514

49.T Fojo , C. Grady How much is life worth: cetuximab, non-small cell lung cancer and the $440 billion question. J Natl Cancer Inst. 2009;101:10441048.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *